Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Interventions: DRUG: Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
Sponsor: National Cancer Centre, Singapore
Collaborators: MSD Pharma (Singapore) Pte Ltd